Advances in Prenatal Screening: Nuchal Translucency Ultrasonography in the First Trimester

After completing this article, readers should be able to: 1. Define the association between nuchal translucency and Down syndrome. 2. Describe the role of nuchal translucency-based ultrasonography in prenatal screening for Down syndrome in singleton and multiple gestations. 3. Characterize the criteria for good nuchal translucency ultrasonographic technique. 4. Identify the limitations of implementing first trimester screening in the general obstetric population. Prenatal screening for Down syndrome and other aneuploidies has advanced significantly since its advent in the 1980s. Antenatal screening for Down syndrome began by selecting women older than age 35 years as candidates for amniocentesis. Maternal serum screening for Down syndrome in the second trimester started in the mid-1980s, with low levels of the analyte alpha-fetoprotein (AFP) associated with an increased risk of fetal Down syndrome. The panel of serum analytes has expanded considerably and generally includes four markers, known as the “quad test,” comprised of AFP, human chorionic gonadotropin (hCG), unconjugated estriol, and most recently, inhibin-A. Second-trimester multiple-marker screening and maternal age remain the standard-of-care in prenatal screening for Down syndrome throughout the United States today, although they can detect only 55% (the double screen) to 76% (the quad test) of Down syndrome cases, with a 5% false-positive rate (FPR). Much emphasis in Down syndrome screening research has been placed on finding protocols that increase the detection rate and make screening available at an earlier time in pregnancy. The most significant advance in this front came in the early 1990s, with the ultrasonography marker nuchal translucency (NT) at 10 to 14 weeks’ gestation, in combination with maternal serum markers of free beta-hCG and pregnancy-associated plasma protein A (PAPP-A). This review focuses on ultrasonographic screening for Down syndrome in the first trimester. Fetal NT refers to the normal subcutaneous fluid-filled space between the back of the neck and the overlying skin (Fig. …

[1]  D. Nyberg,et al.  Sonographic screening for fetal aneuploidy: first trimester. , 2001, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[2]  K. Nicolaides,et al.  Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[3]  F. Malone,et al.  First-trimester screening for aneuploidy: research or standard of care? , 2000, American journal of obstetrics and gynecology.

[4]  F. Malone,et al.  First trimester screening for aneuploidy: nuchal translucency sonography. , 1999, Seminars in perinatology.

[5]  F. Malone,et al.  First trimester screening for structural fetal abnormalities: nuchal translucency sonography. , 1999, Seminars in perinatology.

[6]  N. Wald,et al.  Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. , 1999, The New England journal of medicine.

[7]  K. Nicolaides,et al.  Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study , 1999, BMJ.

[8]  A. Berger What is fetal nuchal translucency? , 1999, BMJ.

[9]  J. Haddow,et al.  Screening of maternal serum for fetal Down's syndrome in the first trimester. , 1998, The New England journal of medicine.

[10]  A. Mcgregor,et al.  US Public Health Service sets out plan for xenotransplantation , 1998, The Lancet.

[11]  A. Mcgregor Gro Harlem Brundtland secures top job at WHO , 1998, The Lancet.